Today the occupational health and safety risk involved when handling most anticancer drugs is well recognized and, as a result of regulatory requirements, safety measures have been established. There is little knowledge about the occupational hazard posed by handling monoclonal antibodies assigned to ATC Class L01XC. The aim of our study was to evaluate the occupational risk of monoclonal antibodies. Using the information obtained in a systematic review of the literature, the potentially dangerous properties of the active drug substances were assessed using a specially devised algorithm. As a result, all monoclonal antibodies in question were categorized as substances with developmental toxicity. In addition, gemtuzumab ozogamicin was categorized as mutagenic. In view of the high molecular weights and the proteinogenic nature of monoclonal antibodies, the route of exposure for health care staff is limited to inhalation, unless there is an accident. Employers should implement the necessary administrative and engineering controls. Employees should adhere to the standards in order to avoid occupational exposure. The hazard assessment algorithm devised and the evaluation procedure may also be used for other drugs considered to be dangerous.
72nd Council Directive 98/24/EC of 7 April 1998 on the protection of the health and safety of workers from the risks related to chemical agents at work (fourteenth individual directive within the meaning of article 16(1) of Directive 89/391/EEC).
2.
Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances of 27 June 1967. AB1.EG L 196 vom 16.8.1967 (and its amendments).
3.
Regulation (EC) NO. 1272/2008 of the European Parliament and of the council of 16. December 2008 on Classification, Labelling and Packaging of Substances and Mixtures amending and repealing Directives 67/548 EEC and 1999/45/EC and amending Regulation (EC) NO. 1907/2006.
4.
Regulation (EC) NO. 1907/2006 of the European Parliament and of the Council of 18 December 2006 on the registration, assessment, authorisation and restriction of chemical substances (REACH), on the creation of a European chemicals agency, on the amendment of Directive 1999/45/EC and on the cancellation of Council Regulation (EEC) No. 793/93, Regulation (EC) No. 1488/94 of the Commission, Council Directive 76/769/EEC and Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC of the Commission.
5.
Technical Rules for Hazardous Substances (TRGS) 905. Verzeichnis krebserzeugender, erbgutverändernder oder fortpflanzungsgefährdender Stoffe. Stand Mai 2008, www.baua.de (accessed December 2009).
6.
Bewertung der gefährlichen Eigenschaften von antineoplastisch wirksamen Arzneistoffen des ATC-Code L01 und L02 zum Schutz der Beschäftigten. Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege (BGW), www.bgw-online.de (accessed February 2010).
7.
Halsen G. and Krämer I.Umgang mit Zytostatika: Gefährdungsbeurteilung - kein Problem?!Krankenhauspharmazie2004; 25: 43-52.
8.
FDA.Summary statement gemtuzumab ozogamicin NDA21-174, www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2a.pdf. (accessed December 2009)
9.
Niosh.Alert: Preventing Occupational Exposures to Antineoplastic and other Hazardous Drugs in Health Care Settings. DHHS (NIOSH) Publication No. 2004-165, www.cdc.gov/niosh (NIOSH Docket105)(2004, accessed May 2009).
10.
American Society of Health-System Pharmacists (ASHP).Technical assistance bulletin on handling hazardous drugs, 1990.
11.
Directive 89/391/EEC on the introduction of measures to encourage measures to encourage improvements in safety and health of workers at work (occupational safety and health framework directive). ABl. EC Nr. L 183 of 29.6.1989 (and its amendments).
12.
Niosh.List of new FDA drugs and warnings fitting NIOSH criteria for hazardous drugs 2006, www.cdc.gov/niosh (NIOSH Docket105) (accessed May 2009).
13.
Niosh.Federal Register Notice: Updating the list of hazardous drugs for the NIOSH alert: Additions and deletions to the NIOSH Hazardous Drug List 2009, www.cdc.gov/niosh (NIOSH Docket105-A) (accessed January 2010).
14.
The European Agency for Evaluation of Medicinal Products.Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH Topic S 6. Step 4. Consensus guideline . 16 July 1997. CPMP/ ICH/302/95, www.eudra.org/emea.html (accessed December 2009).
15.
Yoshida J., Kosaka H., Tomioka K. and Kumagai S.genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J Occup Health2006; 48: 517-522.
Shrim A., Garcia-Bournissen F., Maxwell C., Farine D. and Koren G.Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy-case report and updated literature review. Reprod Toxicol2007; 23: 611-613.
18.
Pant S., Landon MB, Blumenfeld M., Farrar W. and Shapiro CLTreatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol2008; 26: 1567-1569.
19.
Foulkes R.Preclinical safety evaluation of monoclonal antibodies. Toxicology2002; 174: 21-26.
20.
Winter MJ, Nagtegaal ID, van Krieken JH and Litvinov SVThe epithelial cell adhesion molecule (EpCAM) as a morhoregulatory molecule is a tool in surgical pathology. Am J Pathol2003; 163: 2139-2148.
21.
Niosh.Transcript of the NIOSH Public Meeting on Hazardous Drugs List Update. Washington, D.C., August 28, 2007 and related entries, www.cdc.gov/niosh (NIOSH Docket105) (accessed May 2009).
22.
Mir O., Berveiller P., Ropert S., Goffinet F., Pons G., Teluyer J-M., et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol2008; 19: 607-613.
23.
Robinson AA , Watson WJ and Leslie KKTargeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol2007; 8: 738-743.
24.
Loibl S., von Minckwitz G. and Kaufmann M.Mammakarzinom in der Schwangerschaft. Posterpräsentation, 55 . Hamburg: Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, 2004.
25.
Klink DT, van Elburg RM, Schreurs MWJ and van Well GTJ.Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol2008; 2008: 271363.
26.
Fresenius Biotech GmbH.Medical Information. Correspondence of 28.7.2009 and 6.10.2009 .
27.
Langford S. , Fradgley S., Evans M. and Blanks C.Assessing the risk of handling monoclonal antibodies. Hospital Pharmacist2008; 15: 60-64.
28.
NHS Pharmaceutical QualityAssurance Committee.Guidance on handling of monoclonal antibody (MAB) products. Hospital Pharmacist2005; 7/8: 250.
29.
Maillet A., Congy-Jolivet N., Le Guellec S., Vecellio L., Hamard S., Courty Y., et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res2008; 25: 1318-1326.
30.
Pigneret-Bernard S., Saint-Lorant G. and Divanon F.Innocuité des anticorps monoclonaux pour le manipulateur: mythe ou réalité? A propos d une enquete de pratiques professionnelles. J Pharm Clin2008; 27: 227-233.
31.
Saltzman WM , Sherwood JK, Adams DR and Haller P.Long-term vaginal antibody delivery: Delivery systems and biodistribution. Biotechnol Bioeng2000; 67: 253-264.
32.
Brain JDInhalation, deposition and fate of insulin and other therapeutic proteins . Diabetes Technol Ther2007; 9: 4-15.
33.
Folkesson HG , Weström BR and Karlsson BWPermeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand1990; 139: 347-354.
34.
Wikstrom ME and Stumbles PAMouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens. Immunol Cell Biol2007; 85: 182-188.
35.
Hill J., Eyles JE, Elvin SJ, Healey GD, Lukaszewski RA and Titball RWAdministration of antibody to the lung protects mice against pneumonic plague . Infect Immun2006; 74: 3068-3070.
36.
EN 481 Arbeitsplatzatmosphäre.Festlegung der TeilchengröΒenverteilung zur Messung luftgetragener Partikel. Berlin: Beuth Verlag, 1993.
37.
Eickmann U.Methoden der Ermittlung und Bewertung chemischer Expositionen an Arbeitsplätzen . Landsberg/ Lech: Verlagsgruppe Hüthig Jehle Rehm GmbH, ecomed Medizin, 2008.
38.
Wittmann A. , Köver J., Hofmann F. and Kralj N.Übertragbare Blutvolumina nach Nadelstichverletzungen an s.c. Kanülen. Arbeitsmed . Sozialmed. Umweltmed2009; 44: 144-145.
39.
Hazardous Substances Ordinance (Gefahrstoffverordnung-GefStoffV) dated 23 December 2004. Verordnung zur Neufassung der Gefahrstoffverordnung und zur Änderung anderer Verordnungen. Ministerial draft. www.bmas.de/portal/38106 (accessed April 2010).
40.
Technical Rules for Hazardous Substances (TRGS) 400. Risk Assessment for Activities involving Hazardous Substances. GMBl Nr.11/12; March 2008: pp. 211-223, www.baua.de (accessed December 2009).
41.
Roche Pharma AGAbteilung Gesundheitspolitik, personal communication26.3. 2008.
42.
Eickmann U.Methoden der Ermittlung und Bewertung chemischer Expositionen an Arbeitsplätzen . Landsberg/ Lech: Verlagsgruppe Hüthig Jehle Rehm GmbH, ecomed Medizin, 2008.
43.
Council Directive 92/85/EEC of 19 October 1992 concerning the implementation of measures to encourage improvements in the safety and health of pregnant workers, workers who have recently given birth and women who are breastfeeding (tenth individual directive within the meaning of article 16(1) of Directive 89/391/ EEC).
44.
Directive 2004/37/EC of the European Parliament and the Council on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (sixth individual directive in the meaning of article 16(1) of Directive 89/391/EEC).
45.
Bader AA, Schlembach D., Tamussino KF, Pristauz G. and Petru E.Anhydramnios associated with the administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol2007; 8: 79-81.
46.
Sekar R. and Stone PRTrastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol2007; 2: 507-510.
47.
Watson WJHerceptin (Trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol2005 ; 105: 642-643.
48.
Fanale MA, Uyei AR, Theriault RK, Adam K. and Thompson RATreatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer2005; 4: 354-356.
49.
Witzel D., Müller V., Harps E., Janicke F. and deWit M.Trastuzumab in pregnancy associated with poor fetal autcome - letter to the editor. Ann Oncol2007; 12: 1-2.
50.
Waterston AM and Graham J.Effect of adjuvant trastuzumab on pregnancy . J Clin Oncol2006; 24: 321-322.
51.
Warraich Q. and Smith N.Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. Obstetric case reports. J Obstet Gynaecol2009; 29: 147-148.
52.
Rey J., Coso D., Bouayed N., Belchmery N., Ivanov V., Gastaut JA, et al. Rituximab combined with chemotherapy for lymphoma during pregnancy . Leuk Res2009; 33: 8-9.
